Worst Pills, Best Pills

An expert, independent second opinion on more than 1,800 prescription drugs, over-the-counter medications, and supplements

testosterone (ANDRODERM, AVEED, DELATESTRYL, DEPO-TESTOSTERONE, FORTESTA, JATENZO, NATESTO, STRIANT, TESTIM, TESTOPEL, TESTOSTERONE CYPIONATE, TESTOSTERONE ENANTHATE, VOGELXO, XIRON, XYOSTED)


WORST PILLS, BEST PILLS NEWSLETTER ARTICLES

Search results below include Worst Pills, Best Pills Newsletter Articles where your selected drug is a primary subject of discussion.

Testosterone Therapy for Men: More Evidence of Blood Clot Risk
September 2020
In this article, we discuss the results of a recent large observational study that provide added support for the concern that testosterone therapy heightens the risk of dangerous blood clot formation.
Review of Testosterone Products
May 2019
Approximately 10 years ago, testosterone makers launched a massive direct-to-consumer advertising campaign to promote the use of testosterone for normal age-related declines in testosterone in men. Learn why such use of testosterone can be dangerous without providing any proven benefit.
New Evidence Refutes Testosterone Benefits for Age-Related Symptoms
September 2017
In this article, we discuss new data from well-designed randomized controlled trials that show that testosterone treatment in older men with low testosterone blood levels does not improve memory or other cognitive functions and actually increases the buildup of cholesterol in coronary arteries.
New Research Links Testosterone to Risk of Dangerous Blood Clots
April 2017
We review the results of a new study demonstrating that patients using testosterone products have a significantly increased risk of developing life-threatening blood clots in large veins, most often in the legs.
Study Rebuts Health Benefit Claims for Off-Label Testosterone
April 2017
Overall, use of testosterone medications in the U.S. grew by nearly 10-fold from 2000 to 2011, and by 2013, more than 5 million U.S. prescriptions for testosterone were being filled annually. In this article, we discuss new research findings showing that testosterone products fail to provide benefit to many of the men who are using them.
Endocrine Society Recommends Against Routine Use of Compounded Hormones
December 2016
In this article, we explain why FDA-approved bioidentical hormone medications are preferred over custom-mixed (compounded) products for treating hormone-related disorders.
Drug-Induced Hair Loss
July 2016
For most people with hair loss, the condition usually is age-related or due to the genes they inherited from their parents. But for some patients, the cause of the problem can be found in the medicine cabinet. Learn about some commonly used medications that can cause hair loss.
FDA Belatedly Requires Warnings About Heart Attack, Stroke Risks for Testosterone Products
May 2015
On March 3, the Food and Drug Administration finally announced that it was requiring that the labels of all approved prescription testosterone products include a warning about the possible increased risk of heart attacks and strokes. Worst Pills, Best Pills News editor Dr. Michael Carome criticizes the agency for recklessly dragging its feet prior to requiring these warnings.
FDA’s Recent Action on Testosterone Products: Grossly Insufficient
August 2014
The FDA recently required manufacturers of all approved testosterone products to include a general warning on the product labeling about the risk of developing blood clots in veins. Find out why the new warning is dangerously incomplete.
Testosterone Use Linked to Increased Risk of Heart Attacks
March 2014
There is a growing body of evidence indicating that testosterone treatment exposes men to an increased risk of adverse cardiovascular events, such as heart attack and stroke, as well as death. This article reviews the results of two recently published studies that provide the most compelling evidence yet linking testosterone use to increased cardiovascular risk.
Beware: Bioidentical Hormones
September 2010
Many women are using so-called bioidentical hormones, "natural" and implicitly safer versions of prescription drugs such as Premarin, because the latter drugs have been found to cause breast cancer, heart disease and many other serious health problems. The article discusses the fact that these products can be expected to have the same serious adverse effects that con­ventional preparations have and that they have the added disadvantage of not being regulated and thereby having unpredictable amounts of ingredients.
Safety Concerns Lead to Label Changes For Topical Testosterone
May 2010
The article reviews the dangers of testosterone gels and gives recommendations that adults who use testosterone gels should follow.

ADDITIONAL INFORMATION FROM PUBLIC CITIZEN

Search results below include Additional Information from Public Citizen where your selected drug is a primary subject of discussion.

Testimony Before the FDA’s Bone, Reproductive and Urologic Drugs Advisory Committee Regarding Testosterone Undecanoate (Tlando) (HRG Publication #2394)
In testimony before a meeting of the Food and Drug Administration’s (FDA’s) Bone, Reproductive and Urologic Drugs Advisory Committee, Public Citizen urged the committee to recommend that the FDA reject Lipocine’s oral testosterone undecanoate capsules (Tlando) because of serious safety concerns.
Statement: Contrasting Actions by Health Canada and the FDA on Testosterone (HRG Publication #2208)
In a response to the Food and Drug Administration’s (FDA’s) denial of a petition to add a black-box warning to the product labels of all testosterone-containing drugs on the market in the U.S., Public Citizen notes that Health Canada took drastically different action in the same week.
Letter to the FDA Protesting (HRG Publication #2189)
Letter to FDA protesting decision announced today to approve a long-lasting testosterone injection drug, Aveed.
Petition to the FDA for Black Box Warnings on All Testosterone Products (HRG Publication #2184)
Public Citizen petitions the Food and Drug Administration to add a black box warning about the increased risks of heart attacks and other cardiovascular dangers to the product labels of all testosterone-containing drugs presently on the market in the U.S.